Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
In contrast to WHO´s and other expert´s advice, the worst-off countries should be extra prioritised when it comes to COVID-19 vaccine allocation, according to Professor Ole Frithjof Norheim at the University of Bergen.
In a first of its kind study, a University of Houston researcher is examining two common drugs used for dementia in patients with Alzheimer’s disease to determine the extent to which they don’t mix well together and cause a cascading event of side effects, prompting the need for even more medications.
A dentist is getting ready to take on the English Channel in a bid to raise money for a dental charity.
This month, Jim Lafferty will embark on a 12-hour solo swim from Dover to Calais.
Braving water temperatures of around 18°C, he hopes to raise £5,000 for Dentaid, a charity that works to improve oral health in the UK and overseas.
Although the shortest channel route is 21 miles, drifting currents will force Jim to swim around 25 miles to make it across to France. His solo journey will take place between 9 and 15 September.
Jim will swim alongside a boat called High Hopes containing his support team, who will help him to overcome the risks of exhaustion, hypothermia and strong currents. The team includes a pilot and an observer from the Channel Swimming and Piloting Federation.
Why so many COVID-19 patients get blood clots (thrombosis) remains uncertain. But scientists at Uppsala University and the University Hospital have now identified a mechanism they believe to be implicated.
Colgate is launching a dedicated resource page devoted to helping patients suffering with dentine hypersensitivity.
Available at colgate.dentistry.co.uk, the interactive resource page provides readers with an overview on dentine hypersensitivity.
With 50% of sensitivity sufferers not reporting their pain, Colgate hopes this new resource page will help dental professionals diagnose and treat dentine hypersensitivity.
‘We wanted to set this microsite up to provide an educational resource around Colgate Sensitive Pro Relief Toothpaste range to help support dental professionals with managing their patients with dentine hypersensitivity,’ a Colgate spokesperson says.
‘We also want this to be easily accessible to dental professionals. So that they can access it in their own time and provide the opportunity to gain patient samples of Colgate Sensitive Pro relief for their practice.
‘We hope dental professionals will gain a true understanding of how Colgate’s portfolio of sensitive toothpaste can help manage this patient group.
The BCG vaccine has a broad, stimulating effect on the immune system. This gives it an effective preventive action against various infections – possibly also against COVID-19. New studies are investigating that.